Testing Genetic Modifiers of Behavior and Response to Atomoxetine in Autism Spectrum Disorder with ADHD
- 145 Downloads
Frequent non-pathogenic genetic variants may act as moderators of phenotypic severity for complex disorders such as autism spectrum disorder (ASD). We previously identified polymorphisms affecting mRNA expression of candidate genes, including tryptophan hydroxylase 2 (TPH2), dopamine beta hydroxylase (DBH), and dopamine transporter (DAT, SLC6A3). We compare genotypes and (1) clinical response to atomoxetine, (2) scores from the Autism Diagnostic Interview-Revised (ADI-R), and (3) severity of Attention Deficit Hyperactivity Disorder (ADHD) symptoms in a cohort of patients with ASD from multiple study sites. There was no association between CYP2D6 metabolizer status and atomoxetine response. TPH2 rs7305115 genotype was associated with ADI-R Restrictive/Repetitive Behavior score (p = 0.03). DBH rs1611115 genotype was associated with ADI-R Social score (p = 0.002), and Restrictive/Repetitive Behavior score (p = 0.04). The DAT intron 8 5/6 repeat was associated with ADHD symptoms (ABC Hyperactivity p = 0.01 and SNAP ADHD p = 0.03), replicating a previous finding. We find associations between ASD phenotypes and regulatory variants in catecholamine biosynthesis genes. This work may help guide future genetics studies related to ASD.
KeywordsAutism spectrum disorder (ASD) Genetics Restrictive and repetitive behavior Atomoxetine (Strattera) Tryptophan hydroxylase 2 (TPH2) Dopamine transporter (DAT SLC6A3) Attention deficit/hyperactivity disorder (ADHD)
The authors are grateful to Gloria Smith for assistance with sample preparation and to the participating families for volunteering for this research.
Compliance with Ethical Standards
This work was supported by grants from: the National Institute of General Medical Sciences (U01GM092655), Center for Clinical and Translational Science at The Ohio State University (ARRA Pilot Project UL1 RR025755 project 60023888), National Institute of Mental Health to Ohio State University (5R01MH079080), University of Pittsburgh (5R01MH079082–05), and University of Rochester (5R01 MH083247), by Eli Lilly and Co., who provided atomoxetine and placebo, the National Center for Research Resources [University of Rochester CTSA (UL1 RR024160), Ohio State University CTSA (UL1TR001070)] and the National Center for Advancing Translational Sciences of the National Institutes of Health and the United States Air Force Department of Defense (FA7014–09–2-0004 and FA8650–12–2-6359). We are grateful to all the families participating in the CORA registry. The views and opinions expressed in this article are those of the author(s) and do not reflect official policy or position of the National Institutes of Health (NIH), United State Air Force, Department of Defense, or US Government. The use of product(s) and/or manufacturer name(s) is added for clarification only; in no way implies endorsement by the authors, USAF, or DoD of the product(s) or manufacturer(s). The funders have not imposed any restrictions on free access to or publication of the research data.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This study was approved by the institutional review boards at all sites; parents/legal guardians of all participants signed informed consent documents, and children assented if able to do so.
Conflicts of Interest
Dr. Elizabeth Barrie declares that she has no conflict of interest.
Dr. Julia K. Pinsonneault received research funding from the Center for Clinical and Translational Science at The Ohio State University.
Dr. Wolfgang Sadee received research funding from the National Institute of General Medical Sciences.
Dr. Jill Hollway has received research contracts from Forest Research Institute, Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Young Living Essential Oils, and Hoffman-La-Roche.
Dr. Tristram Smith has received research funding from the National Center for Research Resources and the National Institute of Mental Health.
Dr. Benjamin Handen has received research funding from Curemark, Autism Speaks, Eli Lilly and Co., Roche and the National Institute of Mental Health.
Dr. L. Eugene Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and received travel support from Noven.
Dr. Eric Butter has received research funding from CogState, Bracket, Autism Speaks, the Simons Foundation, and Roche.
Ms. Emily Hansen-Kiss, LGC declares that she has no conflict of interest.
Dr. Gail E. Herman has received research funding from the National Center for Advancing Translational Sciences of the National Institutes of Health and the United States Air Force Department of Defense.
Dr. Michael Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for Aevi Genomic Medicine, AMO Pharma, CogState, Inc.; CogState Clinical Trials, Ltd.; Coronado Biosciences; Forest Research; Hoffman-La Roche; Johnson and Johnson; Lumos Pharma, MedAvante, Inc.; Ovid Therapeutics, ProPhase LLC; and Supernus Pharmaceuticals. He also received research funding from the National Institute of Mental Health, and the Ohio State University CTSA.
Glossary of Genetic Terms
a version of the gene, each inherited from a different parent.
a genotype of two different alleles at a given SNP, also referred to as carrier.
a genotype where both alleles are the same at a given SNP.
the allele that is most frequent in the general population.
the allele that is less frequently observed in the population.
single nucleotide polymorphism, also referred to as genetic variant.
homozygous for the major allele.
- AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894–921. https://doi.org/10.1097/chi.0b013e318054e724.CrossRefGoogle Scholar
- Aman, M. G., & Singh, N. N. (2017). Aberrant behavior checklist manual (2nd ed.). East Aurora: Slosson Educational Publications, Inc..Google Scholar
- The American Psychiatric Association (APA). (2013). Diagnostic and statistical manual of mental disorders (5th edn.). Arlington, VA: American Psychiatric Association.Google Scholar
- Barrie, E. S., Weinshenker, D., Verma, A., Pendergrass, S. A., Lange, L. A., Ritchie, M. D., …Sadee, W. (2014) Regulatory polymorphisms in human DBH affect peripheral gene expression and sympathetic activity. Circulation Research 115 (12): 1017–1025.Google Scholar
- Bhaduri, N. & Mukhopadhyay, K. (2008). Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cell Mol Neurobiol, 28(3): 343-350.Google Scholar
- Bray, N. J., Buckland, P. R., Williams, N. M., Williams, H. J., Norton, N., Owen, M. J., & O'Donovan, M. C. (2013). A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. American Journal of Human Genetics, 73(1), 152–161.CrossRefGoogle Scholar
- Carter, A.S., Volkmar, F.R., Sparrow, S. S, … & Schopler, E. (1998). The Vineland adaptive behavior scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28, 287–302.Google Scholar
- Coon, H., Dunn, D., Lainhart, J., Miller, J., Hamil, C., Battaglia, A., … McMahon, W. (2005) Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 135B : 42–46.Google Scholar
- Cottrell, C. E., Bir, N., Varga, E., Alvarez, C. E., Bouyain, S., Zernzach, R., … Herman, G. E. (2011) Contactin 4 as an autism susceptibility locus. Autism Research 4(3): 189–199.Google Scholar
- Coury, D.L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., … Perrin, J.M. (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130 Suppl 2:S69–76.Google Scholar
- Egawa, J., Watanabe, Y., Nunokawa, A., Endo, T., Kaneko, N., Tamura, R., Sugiyama, T., & Someya, T. (2012). A detailed association analysis between the tryptophan hydroxylase 2 (TPH2) gene and autism spectrum disorders in a Japanese population. Psychiatry Research, 196, 320–322.CrossRefPubMedGoogle Scholar
- Garland, E., Black, B., Harris, P., & Robertson D. (2007). Dopamine-beta-hydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol, 293(1): H684-690.Google Scholar
- Handen, B.L., Aman, M.G., Arnold, L.E., Hyman, S.L., Tumuluru, R.V., Lecavalier, L., … Smith T.J. (2015) Atomoxetine, parent training, and their combination in children with autism Spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 54 (11):905–15.Google Scholar
- Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., … Hoekstra, P. J. (2012) A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry 51(7), 733–741.Google Scholar
- Hérault, J., Perrot, A., Barthélémy, C., Büchler, M., Cherpi, C., Leboyer, M.,… Müh, J. P. (1993) Possible association of c-Harvey-Ras-1 (HRAS-1) marker with autism. Psychiatry Research 46(3): 261–267.Google Scholar
- Miles, J.H. (2011). Autism spectrum disorders--a genetics review. Genet Med, 13, 278-294.Google Scholar
- Mossner, R., Walitza, S., Geller, F., Scherag, A., Gutknecht, L., Jacob, C., …, Lesch, K.P. (2006) Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacology 9 : 437–442.Google Scholar
- Mustapic, M., Pivac, N., Kozaric-Kovacic, D., Dezeljin, M., Cubells, J.F. & Mück-Seler D. (2007). Dopamine beta-hydroxylase (DBH) activity and 1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet, 144B(8): 1087-1089.Google Scholar
- Pinsonneault, J. K., Han, D. D., Burdick, K. E., Kataki, M., Bertolino, A., Malhotra, A. K., Gu, H. H., & Sadee, W. (2011). Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology, 36, 1644–1655.CrossRefPubMedPubMedCentralGoogle Scholar
- Ramoz, N., Cai, G., Reichert, J.G., Corwin, T.E., Kryzak, L.A., Smith, C.J., … Buxbaum, J.D. (2006) Family-based association study of TPH1 and TPH2 polymorphisms in autism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B : 861–867.Google Scholar
- Retz, W., Rösler, M., Kissling, C., Wiemann, S., Hünnerkopf, R., Coogan, A., Thome, J., & Freitag, C. (2008). Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm (Vienna), 115(2), 323–329.CrossRefGoogle Scholar
- Ruble, C. L., Smith, R. M., Calley, J., Munsie, L., Airey, D. C., Gao, Y., et al. (2016). Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: Identification of novel HTR2A and antisense (HTR2A-AS1) exons. BMC Genetics, 17, 16.CrossRefPubMedPubMedCentralGoogle Scholar
- Sacco, R., Papaleo, V., Hager, J., Rousseau, F., Moessner, R., Militerni, R., … Persico, A.M. (2007) Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1. BMC Medical Genetics 8: 11.Google Scholar
- Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child & Adolescent Psychiatry, 47, 921–929.CrossRefGoogle Scholar
- Singh, A. S., Chandra, R., Guhathakurta, S., Sinha, S., Chatterjee, A., Ahmed, S., Ghosh, S., & Rajamma, U. (2013). Genetic association and gene-gene interaction analyses suggest likely involvement of ITGB3 and TPH2 with autism spectrum disorder (ASD) in the Indian population. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 45, 131–143.CrossRefGoogle Scholar
- Warren, Z., McPheeters, M.L., Sathe, N., Foss-Feig, J.H., Glasser, A., & Veenstra-VanderWeele, J. (2011). A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics, 127, e1303–e1311.Google Scholar
- World Health Organization (WHO). (1996). ICD-9-CM: International classification of diseases, 9th revision, clinical modification. Salt Lake City: Medicode.Google Scholar
- Zabetian, C. P., Anderson, G. M., Buxbaum, S. G., Elston, R. C., Ichinose, H., Nagatsu, T., Kim, K. S., Kim, C. H., Malison, R. T., Gelernter, J., & Cubells, J. F. (2001). A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. American Journal of Human Genetics, 68(2), 515–522.CrossRefPubMedPubMedCentralGoogle Scholar
- Zhang, Y., Bertolino, A., Fazio, L., Blasi, G., Rampino, A., Romano, R., … Sadée, W. (2007) Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proceedings of the National Academy of Sciences of the United States of America 104, 20552–20557.Google Scholar